One-carbon Therapeutics receives US patent
We are happy to announce that on the 22nd of November 2022 One-carbon Therapeutics received confirmation from the US patent office that a key patent covering the company’s leading drug candidate for the treatment of cancers, inflammation, autoimmune diseases has been granted. The granting of this patent establishes our strong IP portfolio and lays the […]
We are presenting at Bio-Europe 2022, October 24–26, Leipzig, Germany
We look forward to meeting you in person and sharing updates on our progress in bringing innovative medicine to the clinic and providing new options for cancer patients.
One-carbon therapeutics wins ELAVITY Pitch Event
Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program. https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
Pitch prize in Bordeaux
The MTHFD2 program is pitched by CEO Dr Ana Slipicevic at the Meet2Win conference in Bordeaux and wins a pitch price!
Vinnova grants one-carbon therapeutics money
One-carbon therapeutics AB is granted 3,000,000 SEK from Sweden’s innovation agency Vinnova under the Medtech4Health and SweLife programs for further development of the MTHFD2 program.
One-carbon therapeutics AB recieves SME status by EMA
One-carbon therapeutics AB receives SME status by EMA The incentives offered by the SME Regulation give access to: Regulatory assistance: SMEs can benefit from direct regulatory assistance including SME briefing meetings, to provide guidance on the EU regulatory framework and the tools to support innovation. Scientific advice: A substantial fee reduction for scientific advice is available […]
Eir Ventures grants one-carbon
Eir Ventures grants one-carbon a convertible loan to continue pre-seed activities in company and at the same time Magnus Persson becomes the new chairman and Alexander Mata joins the board of directors.
One-carbon is receiving a seed investment
One-carbon is receiving a seed investment from its founders to strengthen the financial situation and secure continuous pre-clinical development of MTHFD2 inhibitors.
AACR21 virtual meeting
Prof Thomas Helleday presents MTHFD2 and other emerging targets such as PKMYT1, MTH1 and Pol Theta at the AACR21 virtual meeting.
